Drug Profile
Research programme: vascular endothelium-targeted therapeutics - Actelion/Johnson & Johnson
Alternative Names: Vascular endothelium-targeted therapeutics research programme - Actelion/Johnson & JohnsonLatest Information Update: 12 Jun 2003
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals; Johnson & Johnson
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Vascular disorders
Most Recent Events
- 12 Jun 2003 Discontinued - Preclinical for Vascular disorders in Switzerland (unspecified route)
- 12 Jun 2003 Discontinued - Preclinical for Vascular disorders in USA (unspecified route)
- 30 Jul 2001 New profile